Trials / Completed
CompletedNCT00387946
Efficacy and Safety of Dianicline Treatment as an Aid to Smoking Cessation in Cigarette Smokers (AMERIDIAN)
An International, Seven-week, Double-blind, Placebo-controlled, Two Parallel Group Study to Assess the Efficacy of Dianicline 40 mg Bid as an Aid to Smoking Cessation in Cigarette Smokers
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 630 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary study objective is to demonstrate the efficacy of dianicline as an aid to smoking cessation in cigarette smokers. The main secondary objectives are to assess the: craving for cigarettes, nicotine withdrawal symptoms, and safety of dianicline.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SSR591813L (dianicline) |
Timeline
- Start date
- 2006-09-01
- Primary completion
- 2007-09-01
- Completion
- 2007-09-01
- First posted
- 2006-10-13
- Last updated
- 2012-02-17
Locations
2 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00387946. Inclusion in this directory is not an endorsement.